Cretostimogene Grenadenorepvec

English name cretostimogene grenadenorepvec

also known as CG0070 · Delta-24-rgd · Cretostimogen grenadenorepvec · delta-24-RGD adenovirus · ON-01 · oncolytic adenovirus expressing GMCSF · oncolytic virus

Trials 15 · a red edge is where a trial was stopped

today NCT07283835 · Ph 2 NCT06567743 · Ph 2 NCT06253845 · Ph 1 NCT06111235 · Ph 3 NCT07145047 · Ph 1/2 NCT04387461 · Ph 2 NCT04452591 · Ph 3 NCT04610671 · Ph 1 NCT06562621 · Ph 1/2 NCT02365818 · Ph 2 NCT02143804 · Ph 2 NCT01438112 · Ph 2/3 NCT01582516 · Ph 1/2 NCT00109655 · Ph 1

200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028202920302031

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 13 trials
Phase 1	NCT06253845	Mar 2024 → Sep 2027 expected	non-invasive bladder urothelial carcinoma	H. Lee Moffitt Cancer Center and Research Institute	Active not recruiting	No outcome recorded
Phase 1	NCT04610671	Oct 2020 → Jul 2024	infiltrating bladder urothelial carcinoma	H. Lee Moffitt Cancer Center and Research Institute	Completed	No outcome recorded
Phase 1	NCT00109655	Apr 2005 → Oct 2008	bladder transitional cell carcinoma	Cell Genesys	Unknown	No outcome recorded
Phase 1/23 trials
Phase 1/2	NCT07145047	Nov 2023 → Dec 2025 overdue	glioblastoma	Mianyang Central Hospital	Recruiting	No outcome recorded
Phase 1/2	NCT06562621	Aug 2018 → Aug 2022	glioblastoma	Beijing Neurosurgical Institute	Completed	No outcome recorded
Phase 1/2	NCT01582516	Jun 2010 → Dec 2014	brain neoplasm, glioblastoma	Erasmus Medical Center	Completed	No outcome recorded
Phase 25 trials
Phase 2	NCT07283835	Dec 2025 → Dec 2027 expected	bladder papillary urothelial carcinoma, non-invasive bladder urothelial carcinoma	Lepu Biopharma Co., Ltd.	Recruiting	No outcome recorded
Phase 2	NCT06567743	Sep 2024 → Mar 2027 expected	non-invasive bladder urothelial carcinoma	CG Oncology, Inc.	Recruiting	No outcome recorded
Phase 2	NCT04387461	Dec 2020 → Mar 2023	non-invasive bladder urothelial carcinoma	CG Oncology, Inc.	Completed	No outcome recorded
Phase 2	NCT02365818	Jun 2015 → Aug 2018	urinary bladder cancer	CG Oncology, Inc.	Completed	No outcome recorded
Phase 2	NCT02143804	Mar 2014 → Mar 2015	high grade malignant neoplasm, urinary bladder carcinoma	CG Oncology, Inc.	Withdrawn	No outcome recorded
Phase 2/31 trial
Phase 2/3	NCT01438112	Mar 2014 → Jun 2016	in situ carcinoma, papillary carcinoma, transitional cell carcinoma, urinary bladder cancer	CG Oncology, Inc.	Terminated	No outcome recorded
Phase 32 trials
Phase 3	NCT06111235	Dec 2023 → Nov 2026 expected	non-invasive bladder urothelial carcinoma	CG Oncology, Inc.	Active not recruiting	No outcome recorded
Phase 3	NCT04452591	Oct 2020 → Jun 2030 expected	bladder papillary urothelial carcinoma, non-invasive bladder urothelial carcinoma	CG Oncology, Inc.	Active not recruiting	No outcome recorded
Phase not stated1 trial
—	NCT06443944	—	non-invasive bladder urothelial carcinoma	CG Oncology, Inc.	Available	No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 17 sources stand behind the page.

Field	Value	Cited text
Known as	cretostimogene grenadenorepvec	“Cretostimogene grenadenorepvec is a serotype-5 oncolytic adenovirus designed to selectively replicate in cancer cells with retinoblastoma pathway alterations” PMID 38844794 ↗ Jun 2024 5 NCT04452591 ↗ NCT06443944 ↗ NCT06567743 ↗ NCT07283835 ↗ NCT06111235 ↗
Known as	CG0070	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04387461 ↗ 5 NCT02365818 ↗ NCT06253845 ↗ NCT00109655 ↗ NCT01438112 ↗ NCT04610671 ↗
Known as	Cretostimogen grenadenorepvec	ChEMBL registry synonym — accepted as the source's own label CHEMBL5095454 ↗
Known as	Delta-24-rgd	“Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma” NCT01582516 ↗ 1 “testing the oncolytic adenovirus Delta24-RGD to treat glioblastoma patients.” NCT01582516 ↗
Known as	delta-24-RGD adenovirus	“delta-24-RGD adenovirus” NCT01582516 ↗
Known as	ON-01	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06562621 ↗
Known as	oncolytic adenovirus expressing GMCSF	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02143804 ↗
Known as	oncolytic virus	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07145047 ↗
Action	Deplete	“designed to preferentially replicate in and kill cancer cells.” NCT06253845 ↗
Modality	Other / unclassified	“oncolytic viral agent” NCT07145047 ↗
Route	Other	“Intravesical administration of CG0070 (in suspension) directly into the bladder” NCT00109655 ↗